Locally Advanced Pancreatic Cancer, Pancreatic Cancer
Conditions
Brief summary
Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10 cycles of therapy. Investigators therefore will evaluate FOLFOX-A in a phase II study for patient with locally advanced pancreatic cancer.
Detailed description
See summary above
Interventions
DRUGFOLFOXA
Schema: 1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\* Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days. Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.) * It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment * Antiemetics will be administered as per standard institutional policy.
Sponsors
Rhode Island Hospital
Brown University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically or cytologically confirmed pancreatic ductal adenocarcinoma. Patients with pathology or cytology showing carcinoma of pancreas or adenosquamous of the pancreas are also eligible. * Locally advanced pancreatic cancer, including patients defined by Callery19 as unresectable and borderline resectable are eligible: * Measurable disease as per RECIST 1.1 * No prior chemotherapy for pancreatic cancer. * No major surgery within 3 weeks of the start of study treatment. Patients must have recovered from the side effects of any major surgery at the start of study treatment. For questions on if a surgery is deemed major, definition by surgeon can be used for clarification. Laparoscopy and central venous catheter placement are not considered major surgery. * No prior invasive malignancy within the prior two years. However, patients with an early stage malignancy that is not expected to require treatment in the next 2 years (such as early stage, resected breast cancer or asymptomatic prostate cancer) are eligible. * ECOG performance status 0 or 1. * Age ≥ 18 * Not pregnant and not nursing. Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to beginning of treatment. Post-menopausal women (surgical menopause or lack of menses \>24 months) do not need to have a pregnancy test, please document status. * Women of childbearing potential and sexually active males must use an effective contraception method 28 days prior to treatment, during treatment and for three months after completing treatment (men are to use contraception for six months post last dose of drug). Documentation of this being discussed required. * Required Initial Laboratory Values: * Neutrophils ≥ 1,500/mm3 * Platelet count ≥ 100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample) * Hemoglobin \> 9.0g/dL * Creatinine ≤ 1.5 mg/dL -or- creatinine clearance ≥ 60 mL/min * Total bilirubin \<1. 5 x ULN * AST (SGOT) & ALT (SGPT) ≤ 2.5 x ULN * Alkaline phosphatase \< 2.5xULN. (Patients with elevated alkaline phosphatase, total bilirubin, AST and ALT, who have subsequently undergone biliary stenting and their liver tests are improving, do not need to wait for their alkaline phosphatase to become \< 2.5x ULN if their total bilirubin, AST and ALT have improved to within required study levels and the alkaline phosphatase is decreasing.)
Exclusion criteria
* Patients with metastatic disease * Prior hypersensitivity to Oxaliplatin or Abraxane ® that in the investigators opinion would put the patient at risk if re-exposed * Preexisting neuropathy is not allowed from any cause. * Patients with serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive FOLFOX-A * Patients with unstable biliary stents or with plastic stents. Information on type of stent is required at registration. * Patients with active infection or fever (patients on antibiotics for infection or patients getting over a cold or seasonal virus are not excluded), or known historical or active infection with HIV, hepatitis B, or hepatitis C. * Patients with active sepsis or pneumonitis. * Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies that in the investigator's opinion would put the patient at an increased risk. * Uncontrolled diabetes. If patient has diabetes, confirmation on status (controlled or uncontrolled) required at registration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. | From date of start of treatment, until the date of first documented progression, whichever came first, assessed up to 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A | During treatment (approximately every 2 weeks for up to 6 months), then approximately every 4 months for for a maximum of 5 years |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| FOLFOXA Schema:
1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*
Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment
* Antiemetics will be administered as per standard institutional policy. | 28 |
| Total | 28 |
Baseline characteristics
| Characteristic | FOLFOXA |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 16 Participants |
| Age, Categorical Between 18 and 65 years | 12 Participants |
| Age, Continuous | 66 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants |
| Race (NIH/OMB) White | 22 Participants |
| Region of Enrollment United States | 28 participants |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 24 / 28 |
| other Total, other adverse events | 28 / 28 |
| serious Total, serious adverse events | 8 / 28 |
Outcome results
Primary
Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.
Time frame: From date of start of treatment, until the date of first documented progression, whichever came first, assessed up to 3 years
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| FOLFOXA | Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. | Complete Response | 0 Participants |
| FOLFOXA | Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. | Partial Response | 12 Participants |
| FOLFOXA | Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. | Stable Disease | 12 Participants |
| FOLFOXA | Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. | Progressive Disease | 4 Participants |
Secondary
Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A
Time frame: During treatment (approximately every 2 weeks for up to 6 months), then approximately every 4 months for for a maximum of 5 years
| Arm | Measure | Value (MEAN) |
|---|---|---|
| FOLFOXA | Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A | 12.3 months |